The company plans a phased launch for all G7 iOS users everywhere by the end of the second quarter of this year. This means G7 soon becomes the only CGM system that can connect directly to Apple Watch without needing to carry an iPhone. Those who use G7 can access this feature as soon as it launches in their country.
On top of the watch feature, Dexcom announced positive data backing its CGMs and their connectivity to automated insulin delivery (AID). Additionally, the company launched Dexcom ONE+ in new geographies and has more data backing its technology.
The company plans to present much of this evidence and data at ATTD this week in Florence, Italy.
“As the pioneer in biosensing, since last year’s ATTD, Dexcom has moved at an extraordinary pace,” Dexcom Chair, President and CEO Kevin Sayer said. “We launched G7 in 16 additional countries, released Dexcom ONE+ and are today announcing the phased launch of ‘Direct-to-watch’, that’s two best-in-class products and a feature designed to empower even more people living with diabetes. Globally, we’ve expanded access to Dexcom products by over 5 million people.”
AID connectivity continues to impress
Dexcom said it plans to present data demonstrating the clinically meaningful outcomes resulting from the use of its CGM with AID system. The data includes results from the CGM with both the Tandem Diabetes Care t:slim X2 pump and Insulet Omnipod 5.
Tandem became the first to connect its AID system with Dexcom G7 in December 2023. Insulet said last month that it began a limited rollout of its Omnipod 5 with G7 as well. According to Dexcom, it expects G7 integration with the new Tandem Mobi pump in the second quarter as well.
One study looked at Omnipod 5 using the previous-generation G6, showing maintained glycaemic outcome improvements for up to two years. Despite the long duration of the study, event rates for severe hypoglycaemia and diabetic ketoacidosis remained low at 2.04 and 0.24 events per 100 person-years.
Real-world evidence from 3,000 people using Tandem’s system demonstrated lower rates for both severe hypoglycaemia and diabetic ketoacidosis over 12 months compared to historic rates. Dexcom also said adult participants spent more than 70% CGM time in range. Pediatric patients achieved 60% CGM time in range.
More good news from Dexcom
In addition to all the AID launches, Dexcom began the ONE+ launch in Europe about a month ago. It says the system has now launched in eight markets within one month of first becoming available.
On top of that, the company has plans to present a first-of-its-kind study linking CGM benefits to mortality reduction in those with type 1 or type 2 diabetes with insulin at ATTD. Dexcom said this indicates broad benefits extending beyond glucose lowering in patients with diabetes on insulin.
New global user data also showed a clinically meaningful reduction in HbA1c for people managing type 2 diabetes with a GLP1 and using a CGM compared to groups not using CGM. Among type 2 populations, the more regularly users wore a Dexcom CGM, the more time they spent in range.
Dexcom also said a study of people treating their type 2 diabetes with basal insulin found the company’s CGM glucose level visualization improved the understanding of the impact of treatment and lifestyle decisions on glucose levels, plus the impact of those glucose levels on additional health issues.
“The breadth of studies and outcomes showcased here at ATTD demonstrates the crucial role that Dexcom CGM can play in the treatment of type 2 diabetes,” said Dr. Thomas Grace, head of clinical advocacy and outcomes at Dexcom. “From demonstrating a clinically significant decrease in HbA1c to increasing time in range and generally improving well-being, the results speak for themselves. We also continue to see studies confirm that whilst GLP1s are an effective initial treatment for those living with type 2 diabetes the use of Dexcom CGM can strengthen their impact and provide an alternative for sustained long-term metabolic health improvement.”
